Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07408089 · ClinicalTrials.gov registry record · Phase 1
Study of the Kinesin Oral Molecular Degrader BBI-940 in Subjects With Advanced or Metastatic Breast Cancer
A Phase 1 study of Breast Cancer and Metastatic Breast Cancer, sponsored by Boundless Bio.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 96
- Enrollment target
- 5
- Study locations
NCT07408089 is a Phase 1 study of Breast Cancer and Metastatic Breast Cancer that is actively recruiting participants, run by Boundless Bio. The registered enrollment target is 96 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (97% lower). The trial reports 5 study locations across 2 states.
The verdict
NCT07408089, a Phase 1 study of Breast Cancer and Metastatic Breast Cancer, is actively recruiting participants, sponsored by Boundless Bio.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 96 participants
- Enrollment target
- 5
- Study locations
Study Summary
This is a first-in-human, open-label, Phase 1 study evaluating BBI-940, an investigational kinesin oral molecular degrader, administered as monotherapy or in combination with fulvestrant in adults with advanced or metastatic breast cancer.
Conditions Studied
Interventions
- DRUG Fulvestrant
- DRUG BBI-940
Study Locations (5)
Texas
- NEXT Oncology - Austin
- NEXT Oncology - Houston
- NEXT Oncology - San Antonio
- The START Center for Cancer Care - San Antonio
Virginia
- NEXT Oncology - Fairfax
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 96 participants |
| Start Date | 2026-02-25 |
| Est. Completion | 2029-05-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07408089
The ClinicalTrials.gov registry entry for NCT07408089 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 96 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (97% lower). The listed sponsor is Boundless Bio, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Breast Cancer appearing as the primary indexed condition, and to 2 interventions - of which Fulvestrant is the first listed.
NCT07408089 reports 5 study locations spanning 2 distinct geographic areas - top geographies include Texas, Virginia.
Frequently Asked Questions
What is clinical trial NCT07408089 about?
NCT07408089 is a clinical study titled "Study of the Kinesin Oral Molecular Degrader BBI-940 in Subjects With Advanced or Metastatic Breast Cancer". This is a first-in-human, open-label, Phase 1 study evaluating BBI-940, an investigational kinesin oral molecular degrader, administered as monotherapy or in combination with fulvestrant in adults with advanced or metastatic breast cancer.
What is the current status of trial NCT07408089?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 96 participants. The study started on 2026-02-25. Estimated completion is 2029-05-31.
What conditions does trial NCT07408089 study?
This clinical trial studies the following conditions: Breast Cancer, Metastatic Breast Cancer, Advanced Breast Cancer.
What interventions are being tested in trial NCT07408089?
The interventions under investigation include: Fulvestrant (DRUG), BBI-940 (DRUG).
Who is sponsoring clinical trial NCT07408089?
This trial is sponsored by Boundless Bio, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07408089 being conducted?
This trial has 5 study locations across Texas, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
VS-6766+Abema+Fulv in Met HR+/HER- BC
RECRUITING · Phase 1
-
KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer
RECRUITING · Phase 1
-
Focused Ultrasound and Gemcitabine in Breast Cancer
RECRUITING · Phase 1
-
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
RECRUITING · Phase 1
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.